Unlike other targets such as CD33 and CD123, CLL-1 is not expressed on normal HSCs, which can ensure hematopoietic recovery, therefore provide a potential therapeutic target for AML treatment (48). This evidence concerns the gene CD33 and acute myeloid leukemia.